ABSTRACT
The article analyzes the results of studying the effects of antihypertensive treatment with the use of agonists dopamine receptors on clinical and hemodynamic and neurohumoral indicators in hypertensive patients with concomitant obesity. Special role is given to the patogenetice factor as dopamine and his relationship with the renin - angiotensin.- aldosterone system, endothelial function, which are aimed at the regulation of blood pressure and obesity formation and progression.
Subject(s)
Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Bromocriptine/therapeutic use , Dopamine Agonists/therapeutic use , Hypertension/drug therapy , Obesity/drug therapy , Adult , Aldosterone/blood , Angiotensin II/blood , Blood Pressure/drug effects , Body Mass Index , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cholesterol, VLDL/blood , Dopamine/blood , Female , Humans , Hypertension/blood , Hypertension/complications , Hypertension/physiopathology , Male , Middle Aged , Obesity/blood , Obesity/complications , Obesity/physiopathology , Receptors, Dopamine/metabolism , Renin-Angiotensin System/drug effects , Triglycerides/bloodABSTRACT
Silent myocardial ischemia (SMI) is a poor prognostic sign of cardiac events development, such as myocardial infarction and sudden cardiac death. This article presents the last decade research findings dedicated exploring mechanisms of SMI development and prognostic value in patients with coronary heart disease.
Subject(s)
Death, Sudden, Cardiac/pathology , Ganglia, Sympathetic/pathology , Myocardial Infarction/pathology , Myocardial Ischemia/pathology , Asymptomatic Diseases , Death, Sudden, Cardiac/etiology , Disease Progression , Electrocardiography , Female , Ganglia, Sympathetic/metabolism , Humans , Male , Myocardial Infarction/diagnosis , Myocardial Infarction/etiology , Myocardial Infarction/metabolism , Myocardial Ischemia/complications , Myocardial Ischemia/diagnosis , Myocardial Ischemia/metabolism , Nociception/physiology , Opioid Peptides/metabolism , Receptors, Purinergic P1/metabolism , Risk FactorsABSTRACT
The discovery of 5 subtypes of dopamine receptors revealed their important role in development of arterial hypertension and obesity. Reduce of their functional activity or number with age conduces to the increase of tone of the sympathetic nervous system, dyspoiesis of leptin, hyperphagia, development of obesity and arterial hypertension. Prescription of dopamine agonists conduces to reduction of in, normalization of leptin, diminishing of appetite and body mass, decrease of blood pressure. Combination of arterial hypertension and obesity is recommended to determine dopamine excretion and to appoint dopamine agonists at level of < 600 nmol/24 hours.
Subject(s)
Bromocriptine/therapeutic use , Dopamine Agonists/therapeutic use , Hypertension/metabolism , Obesity/metabolism , Receptors, Dopamine/metabolism , Adult , Aged , Appetite/drug effects , Arterial Pressure/drug effects , Body Weight/drug effects , Bromocriptine/pharmacology , Dopamine/blood , Dopamine/urine , Dopamine Agonists/pharmacology , Female , Humans , Hypertension/complications , Hypertension/drug therapy , Leptin/blood , Male , Middle Aged , Norepinephrine/blood , Obesity/complications , Obesity/drug therapy , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/metabolismABSTRACT
Hypoxia accompanied chronic obstructive pulmonary disease leads to hypercoagulation, vessels' inflammation, imbalance of oxidative and antioxidative systems. These pathological changes cause arterial hypertension, corpulmonale, metabolism disturbance of the whole organism.
Subject(s)
Cardiovascular Diseases/etiology , Hypertension, Pulmonary/complications , Hypoxia/complications , Inflammation/complications , Pulmonary Disease, Chronic Obstructive/complications , Adipose Tissue/metabolism , Adipose Tissue/pathology , Blood Vessels/metabolism , Blood Vessels/pathology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Disease Progression , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Humans , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/pathology , Hypoxia/metabolism , Hypoxia/pathology , Inflammation/metabolism , Inflammation/pathology , Oxidation-Reduction , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/pathologyABSTRACT
Violations gumoralis and cellular immunity examine as one of anchormen of pathogenetic mechanisms development of ischemic heart trouble. These literatures over, that testifying to development of disbalance of subpopulations of T- and B-lymphocitis, are brought, and also levels of immunoglobulin for patients with the stable and unstable flow of ischemic heart trouble.
Subject(s)
Acute Coronary Syndrome/immunology , Atherosclerosis/immunology , Chlamydophila Infections/immunology , Immunity, Cellular , Immunity, Humoral , Acute Coronary Syndrome/complications , Acute Coronary Syndrome/pathology , Atherosclerosis/complications , Atherosclerosis/pathology , B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/pathology , Chlamydophila Infections/complications , Chlamydophila Infections/pathology , Chlamydophila pneumoniae/immunology , Cytokines/immunology , Endotoxins/immunology , Humans , Severity of Illness Index , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/pathologyABSTRACT
In the article literature data about application of alpha-lipoic acid in medical practice are summarized. The article presents characteristic of chemical structure and functional activity of alpha-lipoic acid. LA is marketed primarily as a "weight loss" and "energy" supplement and has been branded as antioxidants. Later LA has been the subject of numerous research studies and clinical trials. LA was shown to be hepatoprotective, to improve liver circulation and treat chronic liver diseases, including jaundice hepatitis, cirrhosis, and hepatic coma, to treat diabetes, and diabetic neuropathy to alter carbohydrate metabolism, atherosclerosis, coronary atherosclerosis and many others diseases. One of the most studied clinical uses of LA is the treatment of diabetes and diabetic neuropathy LA has also been used experimentally and/or clinically to prevent organ dysfunction, reduce endothelial dysfunction and improve albuminuria, treat or prevent cardiovascular disease. LA is "small" drug with very big potential.
Subject(s)
Coronary Artery Disease/drug therapy , Diabetic Neuropathies/drug therapy , Liver Diseases/drug therapy , Thioctic Acid/therapeutic use , Albuminuria/drug therapy , Albuminuria/metabolism , Animals , Antioxidants/chemistry , Antioxidants/metabolism , Antioxidants/therapeutic use , Carbohydrate Metabolism/drug effects , Clinical Trials as Topic , Coronary Artery Disease/metabolism , Cytoprotection , Diabetes Mellitus/drug therapy , Diabetes Mellitus/metabolism , Diabetic Neuropathies/metabolism , Humans , Liver/blood supply , Liver/drug effects , Liver/metabolism , Liver Diseases/metabolism , Oxidative Stress/drug effects , Thioctic Acid/chemistry , Thioctic Acid/metabolismABSTRACT
We performed an analysis of scientific studies about arterial stiffness impacting on cardiovascular diseases and special mechanisms of its developing. One of these mechanisms is hypoxie endothelial damage. Pulse pressure, aortic pulse wave velocity, the shape of the blood pressure curve, rheography, rheovasography are the methods for determinating arterial stiffness.
